Absorbable cyanoacrylate as a vascular hemostatic sealant: A preliminary trial

Worthington G. Schenk, William D. Spotnitz, Sandra G. Burks, Peter H. Lin, Ruth L. Bush, Alan B. Lumsden

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

No absorbable cyanoacrylate tissue adhesive for safe internal surgical use is available. This prospective multicenter preliminary study was designed to evaluate the safety and effectiveness of an investigational absorbable cyanoacrylate (IAC) as an adjunct to hemostasis in arteriovenous shunt (AVS) procedures for dialysis access. Consenting adults (10) underwent placement of expanded polytetrafluoroethylene (ePTFE) upper extremity vascular grafts for AVS access using continuous 5-0 or 6-0 polypropylene after heparinization (≥3,000 units IV). Arterial anastomoses were evaluated after sealing with IAC followed by 120 seconds of polymerization time. After vascular clamp removal, the mean time to hemostasis was 9.1 ± 28.8 seconds. Additionally, 90 per cent (9/10) and 100 per cent (10/10) achieved hemostasis by 1 and 5 minutes, respectively. No patients required further adjunctive hemostatic measures. Adverse event safety data analysis through 12 weeks revealed occlusion of graft or vessel in four patients and graft thrombosis in one patient, all thought unrelated to sealant use. Other unrelated adverse events (bleeding, death, deep venous thrombosis, edema, erythema, hematoma, infection, and rash) occurred in single patients. Thus, IAC could be a useful sealant for vascular procedures with a potentially satisfactory safety profile. Larger, randomized, multicenter, prospective trials to further evaluate the use of this material are indicated and appropriate.

Original languageEnglish (US)
Pages (from-to)658-661
Number of pages4
JournalAmerican Surgeon
Volume71
Issue number8
StatePublished - Aug 1 2005

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Absorbable cyanoacrylate as a vascular hemostatic sealant: A preliminary trial'. Together they form a unique fingerprint.

Cite this